English

ImDrug: A Benchmark for Deep Imbalanced Learning in AI-aided Drug Discovery

Machine Learning 2022-10-20 v2 Artificial Intelligence Quantitative Methods

Abstract

The last decade has witnessed a prosperous development of computational methods and dataset curation for AI-aided drug discovery (AIDD). However, real-world pharmaceutical datasets often exhibit highly imbalanced distribution, which is overlooked by the current literature but may severely compromise the fairness and generalization of machine learning applications. Motivated by this observation, we introduce ImDrug, a comprehensive benchmark with an open-source Python library which consists of 4 imbalance settings, 11 AI-ready datasets, 54 learning tasks and 16 baseline algorithms tailored for imbalanced learning. It provides an accessible and customizable testbed for problems and solutions spanning a broad spectrum of the drug discovery pipeline such as molecular modeling, drug-target interaction and retrosynthesis. We conduct extensive empirical studies with novel evaluation metrics, to demonstrate that the existing algorithms fall short of solving medicinal and pharmaceutical challenges in the data imbalance scenario. We believe that ImDrug opens up avenues for future research and development, on real-world challenges at the intersection of AIDD and deep imbalanced learning.

Keywords

Cite

@article{arxiv.2209.07921,
  title  = {ImDrug: A Benchmark for Deep Imbalanced Learning in AI-aided Drug Discovery},
  author = {Lanqing Li and Liang Zeng and Ziqi Gao and Shen Yuan and Yatao Bian and Bingzhe Wu and Hengtong Zhang and Yang Yu and Chan Lu and Zhipeng Zhou and Hongteng Xu and Jia Li and Peilin Zhao and Pheng-Ann Heng},
  journal= {arXiv preprint arXiv:2209.07921},
  year   = {2022}
}

Comments

29 pages, 7 figures, 8 tables, a machine learning benchmark submission